Benign Prostatic Hyperplasia Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A 2-week treatment with 5-azacytidine improved the hypercontractility state in prostate from obese mice: Role of the nitric oxide-cyclic guanosine monophosphate signalling pathway
In conclusion, our study paves the way to develop or repurpose therapies that recover the expression of eNOS and sGC and, hence, to improve prostate function in BPH.PMID:38452757 | DOI:10.1111/1440-1681.13851 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 7, 2024 Category: Drugs & Pharmacology Authors: Ana Carolina Ghezzi Gabriela Reolon Passos Mariana Gon çalves de Oliveira Akila Lara Oliveira Guilherme Rossi Assis-Mendon ça Glaucia Coelho de Mello Edson Antunes Fabiola Zakia Monica Source Type: research

Medical Advancements in Benign Prostatic Hyperplasia Treatments
AbstractPurpose of ReviewThis review aims to identify and summarize the current literature on the most recent therapeutic agents and combination strategies for the medical management of lower urinary tract symptoms resulting from benign prostatic hyperplasia.Recent FindingsThe latest advancements in BPH therapy have been in combination strategies. Alpha blockers continue to be the mainstay of treatment, but research is exploring the synergistic benefits of combining them with 5-alpha reductase inhibitors (5-ARIs), phosphodiesterase-5 (PDE5) inhibitors, and beta-3 agonists.SummaryThe alpha-blocker + 5-ARI combination r...
Source: Current Urology Reports - March 7, 2024 Category: Urology & Nephrology Source Type: research

Analysis of risk factors for complications following transurethral resection of the prostate
CONCLUSIONS: The preoperative Quality of Life score is an independent risk factor for the occurrence of Grade I-II complications after transurethral resection of the prostate. The International Prostate Symptom Score is an independent risk factor for the occurrence of Grade III-IV complications after transurethral resection of the prostate.PMID:38436180 | DOI:10.26355/eurrev_202402_35476 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - March 4, 2024 Category: Drugs & Pharmacology Authors: R Meng Z-P Zhai C Zuo W-N Wang Source Type: research

Analysis of risk factors for complications following transurethral resection of the prostate
CONCLUSIONS: The preoperative Quality of Life score is an independent risk factor for the occurrence of Grade I-II complications after transurethral resection of the prostate. The International Prostate Symptom Score is an independent risk factor for the occurrence of Grade III-IV complications after transurethral resection of the prostate.PMID:38436180 | DOI:10.26355/eurrev_202402_35476 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - March 4, 2024 Category: Drugs & Pharmacology Authors: R Meng Z-P Zhai C Zuo W-N Wang Source Type: research